{"protocolSection": {"identificationModule": {"nctId": "NCT00591760", "orgStudyIdInfo": {"id": "GH replacement in CHF"}, "organization": {"fullName": "Federico II University", "class": "OTHER"}, "briefTitle": "Growth Hormone Deficiency in Chronic Heart Failure: A Preliminary Trial", "officialTitle": "Correction of Growth Hormone Deficiency in Patients With Chronic Heart Failure: a Randomized, Controlled, Single-blind Study"}, "statusModule": {"statusVerifiedDate": "2009-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2004-12"}, "primaryCompletionDateStruct": {"date": "2007-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2007-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-12-20", "studyFirstSubmitQcDate": "2007-12-27", "studyFirstPostDateStruct": {"date": "2008-01-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-03-23", "resultsFirstSubmitQcDate": "2012-10-17", "resultsFirstPostDateStruct": {"date": "2012-11-19", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-10-17", "lastUpdatePostDateStruct": {"date": "2012-11-19", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Antonio Cittadini", "oldOrganization": "Federico II University"}, "leadSponsor": {"name": "Federico II University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The aim of this study is to investigate the potential benefits of the correction of growth hormone (GH) deficiency with GH replacement therapy in patients with chronic heart failure due to left ventricular systolic dysfunction.", "detailedDescription": "To date, a wide range of alterations in the GH/IGF-1 axis have been described in patients with chronic heart failure (CHF): reductions in GH levels, reductions in IGF-1 and a pattern of peripheral resistance to GH, in particular in patients with severe heart failure and cardiac cachexia. Unpublished experience of our group support the concept that a considerable amount of CHF-patients have a coexisting Growth Hormone Deficiency (GHD), defined by current guidelines(GH stimulation test).\n\nOur study hypothesis is that correction of GH deficiency in patients with chronic heart failure may exert a beneficial effect on their cardiac function and remodeling, performance status and quality-of-life.\n\nSince this was a preliminary study, no sample size calculation was performed; treatment effects from were sought in left ventricular function (as assessed by cardiac MRI), cardiopulmonary exercise performance, clinical status, vascular reactivity, biochemistry and neurohumoral markers of disease (NT-proBNP)."}, "conditionsModule": {"conditions": ["Heart Failure", "Growth Hormone Deficiency", "Ischemic Heart Disease"], "keywords": ["Heart Failure", "Growth Hormone", "Anabolism", "Anabolic Deficiency", "Hormone replacement"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["INVESTIGATOR"]}}, "enrollmentInfo": {"count": 56, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "GH", "type": "EXPERIMENTAL", "description": "Patients will receive 6 months of substitutive somatotropin (growth hormone) therapy at a dose of 0.012 mg/kg every second day, added to their background optimized CHF therapy", "interventionNames": ["Drug: Somatotropin"]}, {"label": "Placebo", "type": "NO_INTERVENTION", "description": "PLacebo will be admistred with the same devices of GH, also on top of Optimal CHF treatment"}], "interventions": [{"type": "DRUG", "name": "Somatotropin", "description": "Subcutaneous Somatotropin (recombinant human Growth Hormone) 0.012 mg/kg every second day for 6 months", "armGroupLabels": ["GH"], "otherNames": ["rhGH", "Saizen", "NutropinAq"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Peak VO2", "description": "changes in peak VO2", "timeFrame": "6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Heart Failure in ew York Heart Association functional class II to IV\n* Left ventricular end diastolic diameter \\> 60 mm\n* Left ventricular ejection fraction \\< 40%\n* Growth Hormone Deficiency (defined as a peak GH response to intravenous stimulation with GHRH + Arginine \\< 9 ng/dl)\n* Age 18-80 years\n* Clinical stability, guideline-oriented maximal pharmacological therapy\n* Informed consent\n\nExclusion Criteria:\n\n* Active Myocarditis\n* Hypertrophic Cardiomyopathy\n* Active endocarditis\n* Active malignancy\n* End stage renal disease\n* Severe liver disease (Child B-C)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Antonio Cittadini, MD", "affiliation": "Federico II University - Naples", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Luigi Sacc\u00e0, MD", "affiliation": "Federico II University", "role": "STUDY_CHAIR"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Patients recruited during hospital stay were studied after a 3-months period of optimized medical therapy and clinical stability", "recruitmentDetails": "Sixty-three patients with CHF NYHA class II-IV and GH deficiency were enrolled from December 2004 to December 2006. These patients were consecutively selected from a cohort of 158 ambulatory patients referred to our tertiary care center and, to a minor extent, patients hospitalized for CHF.", "groups": [{"id": "FG000", "title": "GH Replacement Therapy", "description": "Patients will receive 6 months of substitutive somatotropin (growth hormone) therapy at a dose of 0,00415 mg/kg a day, added to their background optimized CHF therapy"}, {"id": "FG001", "title": "Control", "description": "Optimal CHF treatment"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "28"}, {"groupId": "FG001", "numSubjects": "28"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "28"}, {"groupId": "FG001", "numSubjects": "28"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "GH Replacement Therapy", "description": "Patients will receive 6 months of substitutive somatotropin (growth hormone) therapy at a dose of 0,00415 mg/kg a day, added to their background optimized CHF therapy"}, {"id": "BG001", "title": "Control", "description": "Optimal CHF treatment"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "28"}, {"groupId": "BG002", "value": "56"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0.0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "32.0"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "24.0"}]}]}]}, {"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "62", "spread": "6"}, {"groupId": "BG001", "value": "62", "spread": "8"}, {"groupId": "BG002", "value": "62", "spread": "4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "9.0"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "47.0"}]}]}]}, {"title": "echocardiography", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "% of ejection fraction", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "30", "lowerLimit": "20", "upperLimit": "70"}, {"groupId": "BG001", "value": "40", "lowerLimit": "20", "upperLimit": "70"}, {"groupId": "BG002", "value": "35", "lowerLimit": "20", "upperLimit": "70"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Peak VO2", "description": "changes in peak VO2", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ml/kg/min", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "GH Replacement Therapy", "description": "Patients will receive 6 months of substitutive somatotropin (growth hormone) therapy at a dose of 0,00415 mg/kg a day, added to their background optimized CHF therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal CHF treatment"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14.5", "spread": "1.0"}, {"groupId": "OG001", "value": "12.9", "spread": "1.0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "1", "eventGroups": [{"id": "EG000", "title": "GH Replacement Therapy", "description": "Patients will receive 6 months of substitutive somatotropin (growth hormone) therapy at a dose of 0,00415 mg/kg a day, added to their background optimized CHF therapy", "seriousNumAffected": 0, "seriousNumAtRisk": 0, "otherNumAffected": 0, "otherNumAtRisk": 0}, {"id": "EG001", "title": "Control", "description": "Optimal CHF treatment", "seriousNumAffected": 0, "seriousNumAtRisk": 0, "otherNumAffected": 0, "otherNumAtRisk": 0}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Prof. Antonio Cittadini", "organization": "Federico II University", "email": "antonio.cittadini@unina.it", "phone": "0039(0)817464375"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000004393", "term": "Dwarfism, Pituitary"}, {"id": "D000006333", "term": "Heart Failure"}, {"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000017202", "term": "Myocardial Ischemia"}, {"id": "D000003324", "term": "Coronary Artery Disease"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "ancestors": [{"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000003327", "term": "Coronary Disease"}, {"id": "D000001161", "term": "Arteriosclerosis"}, {"id": "D000001157", "term": "Arterial Occlusive Diseases"}, {"id": "D000004392", "term": "Dwarfism"}, {"id": "D000001848", "term": "Bone Diseases, Developmental"}, {"id": "D000001847", "term": "Bone Diseases"}, {"id": "D000009140", "term": "Musculoskeletal Diseases"}, {"id": "D000001849", "term": "Bone Diseases, Endocrine"}, {"id": "D000007018", "term": "Hypopituitarism"}, {"id": "D000010900", "term": "Pituitary Diseases"}, {"id": "D000007027", "term": "Hypothalamic Diseases"}, {"id": "D000001927", "term": "Brain Diseases"}, {"id": "D000002493", "term": "Central Nervous System Diseases"}, {"id": "D000009422", "term": "Nervous System Diseases"}], "browseLeaves": [{"id": "M6546", "name": "Coronary Artery Disease", "asFound": "Ischemic Heart Disease", "relevance": "HIGH"}, {"id": "M10543", "name": "Ischemia", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "asFound": "Heart Disease", "relevance": "HIGH"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M19506", "name": "Myocardial Ischemia", "asFound": "Ischemic Heart Disease", "relevance": "HIGH"}, {"id": "M7567", "name": "Dwarfism, Pituitary", "asFound": "Growth Hormone Deficiency", "relevance": "HIGH"}, {"id": "M7566", "name": "Dwarfism", "relevance": "LOW"}, {"id": "M13791", "name": "Pituitary Diseases", "relevance": "LOW"}, {"id": "M6549", "name": "Coronary Disease", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "asFound": "Hormone Deficiency", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M4469", "name": "Arteriosclerosis", "relevance": "LOW"}, {"id": "M4465", "name": "Arterial Occlusive Diseases", "relevance": "LOW"}, {"id": "M5127", "name": "Bone Diseases, Developmental", "relevance": "LOW"}, {"id": "M5126", "name": "Bone Diseases", "relevance": "LOW"}, {"id": "M12097", "name": "Musculoskeletal Diseases", "relevance": "LOW"}, {"id": "M5128", "name": "Bone Diseases, Endocrine", "relevance": "LOW"}, {"id": "M10068", "name": "Hypopituitarism", "relevance": "LOW"}, {"id": "M10077", "name": "Hypothalamic Diseases", "relevance": "LOW"}, {"id": "M5204", "name": "Brain Diseases", "relevance": "LOW"}, {"id": "M5742", "name": "Central Nervous System Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}, {"id": "T2633", "name": "Growth Hormone Deficiency", "asFound": "Growth Hormone Deficiency", "relevance": "HIGH"}, {"id": "T3125", "name": "Isolated Growth Hormone Deficiency", "asFound": "Growth Hormone Deficiency", "relevance": "HIGH"}, {"id": "T2955", "name": "Hypopituitarism", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "BC05", "name": "Musculoskeletal Diseases"}, {"abbrev": "BC10", "name": "Nervous System Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "BC16", "name": "Diseases and Abnormalities at or Before Birth"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M3032", "name": "Anabolic Androgenic Steroids", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}